Acoramidis: Revision history

Filter revisionsshowhide

To date:

Tag filter:

Invert selection

External tools:

For any version listed below, click on its date to view it. For more help, see Help:Page history and Help:Edit summary. (cur) = difference from current version, (prev) = difference from preceding version, m = minor edit, → = section edit, ← = automatic edit summary

curprev 03:3903:39, 22 October 2024 Aadirulez8 talk contribs m 12,738 bytes 0 v2.05 - Fix errors for CW project (Reference before punctuation) undo Tag: WPCleaner

curprev 15:0115:01, 20 October 2024 Mamoun Alhamadseh talk contribs 12,715 bytes +856 Added the original 2013 PNAS article describing the discovery of Acoramidis (AG10) undo
curprev 14:2614:26, 20 October 2024 Mamoun Alhamadseh talk contribs 11,859 bytes +124 The corresponding authors names were not included in refences number 1 undo

curprev 22:3622:36, 19 October 2024 Citation bot talk contribs 11,735 bytes 0 Alter: pmc, date, title, template type. Add: doi, pmid, authors 1-1. Removed URL that duplicated identifier. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by Jay8g | Category:CS1 maint: PMC format | #UCB_Category undo
curprev 21:5921:59, 19 October 2024 Bioinvstr talk contribs 11,735 bytes +7,441 Added references and P1 through to P3 high-level daa undo Tag: Visual edit

curprev 08:2308:23, 31 December 2023 Citation bot talk contribs 4,294 bytes −69 Removed proxy/dead URL that duplicated identifier. | Use this bot. Report bugs. | Suggested by Whywhenwhohow | #UCB_webform 8/661 undo

curprev 22:0422:04, 27 November 2023 OAbot talk contribs m 4,364 bytes +17 Open access bot: doi updated in citation with #oabot. undo

curprev 18:2218:22, 11 November 2023 Buidhe talk contribs 1,774 bytes +70 + undo
curprev 18:2118:21, 11 November 2023 Buidhe talk contribs 1,704 bytes +1,704 ←Created page with '''' Acoramidis''' (AG10) is an developed to treat transthyretin amyloid cardiomyopathy. An alternative treatment is tafamidis.<ref>{{cite web |title=Trial demonstrates potential of acoramidis for transthyretin amyloid cardiomyopathy |url=https://www.escardio.org/The-ESC/Press-Office/Press-releases/Trial-demonstrates-potential-of-acoramidis-for-transthyretin-amyloid-cardiomyopathy |website=www.escardio.org}}</ref><ref>{{cite journal |last1=Masri |fi...'